Discover groundbreaking results from the lidERA study, showcasing giredestrant's potential to redefine treatment for early breast cancer patients.
Erika Mayer, MD, MPH
Advertisement
Erika Mayer, MD, MPH, is a medical oncologist at Dana-Farber Cancer Institute.
Articles by Erika Mayer, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5
